Stockwinners Market Radar for July 01, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:20 EDT Pinterest CFO sells $1.34M in common stock - In a regulatory filing, Pinterest disclosed that its CFO Julia Donnelly sold 30.3K shares of common stock on June 27th in a total transaction size of $1.34M.

20:13 EDT DiaMedica Therapeutics 10% holders buy $6M in common stock - In regulatory filings, DiaMedica Therapeutics disclosed that its 10%-holders Thomas Van Koch and Jan Stahlberg each bought 1.2M shares of common stock on June 28th in respective transaction sizes of $3M. Shares of DiaMedica Therapeutics were up 7.5% afterhours at $3.17.

20:07 EDT Cathie Wood's ARK Investment buys 739K shares of Adaptive Biotechnologies today

20:06 EDT Cathie Wood's ARK Investment bought 204K shares of Recursion Pharmaceuticals

19:01 EDT TechPrecision to delay filing 10-K - In a regulatory filing, the company states: "TechPrecision is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended March 31, 2024 within the prescribed period due to a delay experienced by the Company in compiling the required information with respect to the results of operations of its Stadco operating segment in order to complete its financial statements and other disclosures in the Annual Report. As a result, the Company's independent registered public accounting firm requires additional time to complete its audit of the financial statements for the fiscal year ended March 31, 2024 to be included in the Annual Report. Although the acquisition of Stadco was completed on August 25, 2021, the Company continues to work on integrating Stadco's financial reporting processes and procedures into its larger financial reporting structure."

17:47 EDT Mannatech names James Clavijo as new CFO - Mannatech appointed James Clavijo as Chief Financial Officer of Mannatech effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron, Guided Therapeutics, Aeterna Zentaris, and Tri-source Pharma.

17:03 EDT Motorola Solutions acquires Noggin, terms undisclosed - Motorola Solutions has acquired Noggin, a global provider of cloud-based business continuity planning, operational resilience and critical event management, or CEM, software. The company is headquartered in Sydney, Australia, with a global footprint of customers. Terms of the transaction were not disclosed.

16:35 EDT Hookipa Pharma doses first patient in HB-500 trial - Hookipa Pharma (HOOK) announced that the first person has been dosed in a Phase 1b clinical trial of HB-500, an investigational therapeutic vaccine for the treatment of HIV. As a result, Hookipa achieved a $5M non-dilutive milestone payment under its collaboration and license agreement with Gilead (GILD). The Phase 1b clinical trial will evaluate the safety and tolerability, reactogenicity, and immunogenicity to repeated doses of HB-500 in participants with HIV on suppressive antiretroviral treatment. The Phase 1b design comprises two dose escalation cohorts that will be randomized to receive HB-500 or placebo. The first participant was dosed on July 1 and enrollment is ongoing.

16:35 EDT Cullen/Frost CFO to retire at year-end - Cullen/Frost announced that Jerry Salinas, group executive vice president and CFO of Cullen/Frost and Frost Bank, has decided to retire at the end of 2024. Salinas has worked at Frost since 1986 in several positions, including being named bank and corporate controller in 1989 and treasurer in 1997. He became senior executive vice president and treasurer in 2001 and was named to his current position in 2015.

16:23 EDT iLearningEngines joins the broad-market Russell 3000 July 1 - iLearningEngines announced that as of the opening of trading on July 1, the company officially joined the broad-market Russell 3000 Index as well as other related indexes.

16:21 EDT Twin Disc added to Russell 2000, Russell 3000 indexes - Twin Disc announced that it has been added to the Russell 2000 and Russell 3000 indexes, effective July 1.

16:19 EDT Rapid7 to acquire Noetic Cyber, does not see material FY24 ARR impact - Rapid7 announced it has signed a definitive agreement to acquire Noetic Cyber, a cyber asset attack surface management, or CAASM company. The addition of Noetic's CAASM solution to Rapid7's existing cybersecurity solutions will provide more visibility of a customer's environment, including visibility into both internal and external assets, on-premise and in the cloud. Noetic Cyber was co-founded in 2019 by Paul Ayers, Allen Hadden, and Allen Rogers to empower security teams to command their attack surface. The acquisition of Noetic Cyber is expected to close during Rapid7's fiscal third quarter and is not expected to have a material impact on the company's 2024 annualized recurring revenue, or ARR. Following the close of the transaction, Rapid7 is expected to make Noetic Cyber capabilities available to its customers this summer.

16:18 EDT Rapid7 to acquire Noetic Cyber, sees material FY24 ARR impact - Rapid7 announced it has signed a definitive agreement to acquire Noetic Cyber, a cyber asset attack surface management, or CAASM company. The addition of Noetic's CAASM solution to Rapid7's existing cybersecurity solutions will provide more visibility of a customer's environment, including visibility into both internal and external assets, on-premise and in the cloud. Noetic Cyber was co-founded in 2019 by Paul Ayers, Allen Hadden, and Allen Rogers to empower security teams to command their attack surface. The acquisition of Noetic Cyber is expected to close during Rapid7's fiscal third quarter and is not expected to have a material impact on the company's 2024 annualized recurring revenue, or ARR. Following the close of the transaction, Rapid7 is expected to make Noetic Cyber capabilities available to its customers this summer.

16:16 EDT Matrix Service to join Russell 3000 Index on June 28 - Matrix Service announced its addition to the Russell 3000 Index, effective after the close of the U.S. equity markets on June 28 . Membership in the U.S. all-cap Russell 3000(R) Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

16:15 EDT National Vision names Mark Banner as new Chief Stores Officer - National Vision announces the appointment of Mark Banner as the company's new Chief Stores Officer, effective July 8, 2024. Most recently, he served as senior vice president of retail and real estate.

16:14 EDT Y-mAbs Therapeutics appoints Peter Pfreundschuh as CFO - Y-mAbs Therapeutics announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer."Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pretargeted Radioimmunotherapy, or SADA-PRIT, technology platform," said Mr. Rossi. "With Peter on board as our new U.S.-based Chief Financial Officer, we believe we are in a strong position to make strategic decisions that will serve our mission of improving the lives of patients with cancer and other serious diseases. Peter brings a wealth of leadership experience across the healthcare sector with deep experience in developing and commercializing novel pharmaceutical products, and we are excited to welcome him to our team."

16:12 EDT Philip Morris' Swedish Match seeks General Snus risk claims update - The company states: "Experts from Swedish Match USA, Inc., an affiliate of Philip Morris International, presented to the Tobacco Products Scientific Advisory Committee, or TPSAC, on June 26, 2024. The committee, comprised of independent scientific researchers, provides regulatory guidance to the U.S. Food and Drug Administration's Center for Tobacco Products. The half-day meeting was part of the FDA's review of Swedish Match's request to continue marketing General Snus products in the U.S. as Modified Risk Tobacco Products, and to expand permitted use of the reduced risk claim to reach, and transition, more legal-age smokers away from cigarettes. Initially granted by FDA in October 2019, Swedish Match can communicate to legal age consumers that "Using General Snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." Currently that message is accessible only on the General Snus website. Swedish Match presented to the committee real-world evidence showing the claim is delivering on its promise to reduce harm to individual tobacco users and benefit the health of the population and should be renewed. In its renewal submission, Swedish Match is seeking to expand use to additional lawful marketing channels, such as point-of-sale display and direct mail to age-verified consumers."

16:11 EDT Adeia enters into multi-year IP license agreement with X Corp, no terms - Adeia (ADEA) has entered into a multi-year license agreement with X Corp, the owner of the social media platform formerly known as Twitter (TWTR). The agreement also resolves all of the outstanding litigation between the companies. "We are pleased to enter into this agreement and resolve the outstanding litigation with X Corp., a leading technology company and social networking platform, furthering our well-established intellectual property licensing business," said Kevin Tanji, chief legal officer at Adeia. Adeia's fundamental innovations power their customers' next-generation products, delivering breakthroughs in digital experiences for consumer and enterprise applications. The company's IP shapes the way millions of people explore and experience entertainment and enhances billions of devices in an increasingly connected world.

16:08 EDT Bank OZK raises dividend 1c or 2.56% from prior quarter - Bank OZK announced its Board of Directors declared a quarterly cash dividend on the Bank's common stock of 40c per share, up 1c, or 2.56% from the prior quarter. The common stock dividend is payable on July 19 to shareholders of record as of July 12. Bank OZK has increased its quarterly cash dividend on its common stock in each of the last fifty-six quarters.

16:08 EDT DHI Group to reduce current workforce by 7% in restructuring - In a regulatory filing, DHI Group disclosed that on July 1, the company announced an organizational restructuring intended to streamline its operations, drive business objectives, and reduce operating costs. This included a reduction of the company's current workforce by approximately 7%. The restructuring is expected to generate annual cost savings of approximately $4M-$6M. The company estimates that it will incur approximately $1.1M in cash charges related to employee severance and benefits and expects all of the $1.1M to be future cash expenditures. All charges are expected to be recognized in the third quarter of 2024 while the related cash payments are expected to be substantially completed by the end of 2024. "The actions associated with the organizational restructuring are expected to be substantially complete by the end of the third quarter of 2024, subject to local law and consultation requirements. The estimates of the charges and expenditures that the company expects to incur, as well as the estimated cost savings and the timing thereof, are subject to a number of assumptions, including local law requirements in various jurisdictions, and actual amounts may differ materially from estimates. In addition, the company may incur other charges or cash expenditures not currently contemplated due to unanticipated events that may occur in connection with the restructuring," the filing stated.

16:05 EDT Smith Douglas Homes announces leadership changes - The company states: "Smith Douglas Homes announced two significant leadership changes within the organization that will support the company's continued growth and success. First, Eddy Kleid will be taking on the role of Division President for the company's newly established Central Georgia Division. Eddy has been a valued member of the Smith Douglas team since 2017, serving as VP of Finance. During his tenure, Eddy has helped grow the finance team and played an integral part in the Company's recent IPO. Additionally, the company welcomes Joe Thomas as its new SVP of Accounting & Finance. Joe joins from Bank of America Securities, where he served as Director, providing corporate finance, M&A advisory, and capital raising support to REITs, operating companies, sponsors, and private investors in the real estate, homebuilding, gaming, and leisure sectors."

15:37 EDT Blue World Acquisition Corp trading resumes

15:32 EDT Blue World Acquisition Corp trading halted, volatility trading pause

14:31 EDT IBM completes acquisition of StreamSets and webMethods - IBM announced it has completed its acquisition of StreamSets and webMethods from Software AG after receiving all required regulatory approvals. "The acquisition brings together leading capabilities in integration, API management and data ingestion. The acquisition builds on IBM's extensive software portfolio, with StreamSets adding new data ingestion capabilities to IBM's AI and data platform, and webMethods bringing Integration Platform as a Service capabilities to IBM's Automation solutions. IBM's clients and partners will now have access to one of the most modern and comprehensive application and data integration platforms in the industry to drive innovation and prepare business for AI... IBM plans to extend the webMethods iPaaS to support the IBM integration products, giving current customers a path to multi-cloud hybrid integration. By supporting various patterns of integration, including applications, APIs, events, and B2B, IBM will help enable users to compose modern, unified, and seamless applications and services," the company stated.

14:02 EDT Izea's Hoozu announces acquisition of 26 Talent - Hoozu, an influencer marketing agency and a subsidiary of IZEA Worldwide, announces the acquisition of 26 Talent, an Australian talent management agency. "This strategic acquisition strengthens Hoozu's capabilities and expands its footprint in the Asia-Pacific region, in line with IZEA's global M&A strategy," the company stated. The financial terms of the transaction were not disclosed.

13:49 EDT Catcha Investment Corp trading halted, volatility trading pause

12:23 EDT Interactive Brokers reports June DARTs up 20% y/y - Interactive Brokers Group reported its Electronic Brokerage monthly performance metrics for June. Brokerage highlights for the month included: 2.469 million Daily Average Revenue Trades, 26% higher than prior year and 5% higher than prior month. Ending client equity of $497.2B, 36% higher than prior year and 2% higher than prior month. Ending client margin loan balances of $55.1B, 32% higher than prior year and 4% higher than prior month. Ending client credit balances of $107.1B, including $4.1B in insured bank deposit sweeps, 8% higher than prior year and about even with prior month. 2.92 million client accounts, 28% higher than prior year and 2% higher than prior month. 190 annualized average cleared DARTs per client account. Average commission per cleared Commissionable Order of $2.99 including exchange, clearing and regulatory fees.

12:02 EDT Glass Lewis recommends LL Flooring shareholders vote for F9 nominees - F9 Investments, which together with its affiliates collectively owns approximately 8.85% of LL Flooring Holdings common stock and is the Company's largest shareholder, announced that Glass Lewis & Co. has recommended that LL Flooring shareholders vote on F9's GOLD proxy card "FOR" the election of F9's director nominees - Thomas Sullivan, Jason Delves, and Jill Witter - and "WITHHOLD" from LL Flooring's nominees Douglas Moore, Ashish Parmar, and Nancy Taylor in connection with the Company's 2024 Annual Meeting of Shareholders to be held on July 10, 2024. In making its recommendation "FOR" F9's nominees, Glass Lewis noted the following regarding LL Flooring's prospects under incumbent leadership and the need for swift change: "It is not clear at this juncture that the board has a clear vision as to the fair value of the Company or its prospects, nor is it evident there is firm cognizance of the downward pressure on LL's shares arising from the Company's substantially poor performance and significant financial risks...we consider election of F9's slate to represent the most compelling alternative available at what appears to be a fairly critical juncture for LL."

12:01 EDT Warrior Met Coal rises 13.3% - Warrior Met Coal is up 13.3%, or $8.35 to $71.11.

12:00 EDT Tilly's falls -9.6% - Tilly's is down -9.6%, or -58c to $5.45.

12:00 EDT Eve Holding falls -18.3% - Eve Holding is down -18.3%, or -74c to $3.31.

11:32 EDT Vsee Health Inc trading halted, volatility trading pause

10:57 EDT Coinbase to provide crypto custody services for U.S. Marshals Service - The U.S. Marshals Service, an agency within the U.S. Department of Justice that is responsible for asset forfeiture, announced that it selected Coinbase Prime to provide custody and advanced trading services for the agency's "Class 1" digital assets, which it manages centrally in support of federal law enforcement. The USMS conducted a competitive due diligence process that evaluated a range of solutions, ultimately choosing Coinbase due to our strong track record and ability to securely provide institutional-grade crypto services at scale, Coinbase said in a blog post. Coinbase said: "Coinbase has a longstanding history of supporting law enforcement agencies, dating back to the founding of our law enforcement program in 2014. Today, Coinbase works with every major U.S. federal, state, and local law enforcement agency, as well as international agencies on every continent. Growing the cryptoeconomy means promoting safe and efficient markets, and these partnerships are critical to our mission." Reference Link

10:05 EDT Eli Lilly in strategic relationship with Radionetics, pays $140M upfront - Radionetics Oncology announced the formation of a strategic relationship with Eli Lilly "to take forward" Radionetics' proprietary G protein coupled receptor targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140M upfront cash payment. As part of the strategic arrangement, Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1B. During the exercise period, Radionetics will continue to build out a proprietary pipeline of therapeutic assets. These will include small molecule radioligand therapeutics targeting GPCRs using the Radionetics proprietary discovery platform and associated intellectual property.

10:01 EDT Desktop Metal falls -7.7% - Desktop Metal is down -7.7%, or -32c to $3.81.

10:00 EDT Li-Cycle falls -13.0% - Li-Cycle is down -13.0%, or -85c to $5.68.

10:00 EDT Alpha Metallurgical rises 11.3% - Alpha Metallurgical is up 11.3%, or $31.82 to $312.35.

09:48 EDT Peabody Energy rises 6.6% - Peabody Energy is up 6.6%, or $1.45 to $23.57.

09:48 EDT Global Partner Acquisition Corp II trading resumes

09:47 EDT GameStop falls -6.9% - GameStop is down -6.9%, or -$1.70 to $22.99.

09:47 EDT Li-Cycle falls -14.1% - Li-Cycle is down -14.1%, or -92c to $5.61.

09:43 EDT Global Partner Acquisition Corp II trading halted, volatility trading pause

09:40 EDT Orchestra Biomed Holdings Inc trading resumes

09:31 EDT ATI names Kimberly Fields CEO in planned transition - Kimberly Fields today became President and CEO of ATI. In a planned leadership transition, she succeeds Robert Wetherbee, who becomes Executive Chairman. Fields served as ATI's Chief Operating Officer since 2022, becoming President in July 2023.

09:30 EDT Orchestra Biomed Holdings Inc trading halted, volatility trading pause

09:27 EDT California Resources completes Aera Energy combination, provides 2H24 targets - California Resources completed the all-stock combination with Aera Energy. The issuance of shares was approved by CRC shareholders at a special meeting held on June 26, where CRC shareholders voted in favor of the stock issuance necessary for the closing of the combination of CRC and Aera. The pro forma combined net daily production of CRC and Aera averaged 146 thousand barrels of oil equivalent per day during the two months of April and May. The company provided average daily net production and capital guidance for the combined business during the second half 2024. The guidance remains subject to integration of accounting and reporting processes, including but not limited to conforming Aera's accounting policies to CRC. CRC expects to provide updated full-year 2024 guidance with its second quarter 2024 earnings release. The company estimates second half net production to be 140-160 mboepd. Sees second half percentage oil 78%. Sees second half capital $170M-$210M. Effective July 1, Bobby Saadati, CEO of IKAV Energy and James Jackson, managing director, Sustainable Energies at Canada Pension Plan Investment Board, were appointed to serve on CRC's board. The combined company will be run by the current CRC executive team and will continue to be headquartered in Long Beach, California. In connection with closing the transaction, CRC increased its borrowing base from $1.2B to $1.5B and increased the aggregate commitment amount from $630M to $1.1 under its revolving credit facility. Pursuant to the terms of the definitive transaction agreement, Aera's former equity owners received 21.3M shares of common stock of CRC, with an aggregate value of $1.134B based on the price per share as of market close on June 28.

09:26 EDT Marcus to operate former Showplace ICON Theatre in St. Louis Park, Minnesota - Marcus Theatres, a division of The Marcus Corporation, announced that it will take over the operations of the Showplace ICON Theatre & Kitchen at the Shops at West End in St. Louis Park, Minn., after doors closed June 30, 2024. Through an agreement to assume operations with the property's owner, Marcus will reopen the theatre to customers on July 8 , as the Marcus West End Cinema. We're thrilled to extend the Marcus Theatres experience to the Shops at West End," said Mark Gramz, president of Marcus Theatres. "It's an opportunity to continue to engage Marcus movie fans as well as gain new ones and to demonstrate our continued confidence in the theatre business as the summer blockbuster season heats up." Marcus Theatres is the fourth largest theatre chain in the U.S. and the West End Cinema will be the eighth Marcus Theatre in Minnesota. Marcus' extension into West End gives moviegoers additional flexibility to screen movies in the Minneapolis area, which already includes Marcus Oakdale, Rosemount, and Southbridge Crossing Cinemas. It also provides an additional opportunity to grow Marcus Passport, a one-purchase movie ticket bundle that allows moviegoers to see multiple movies in a series for the lowest price at any Marcus Theatre during its run.

09:25 EDT Citizens announces President Jon Stenberg appointed Chief Executive Officer - Citizens, Inc. announces the planned transition of the Chief Executive Officer role. Jon Stenberg, who currently serves as Citizens' President, is appointed to the additional role of Chief Executive Officer effective July 1. Gerald Shields, who has served as CEO and Vice Chairman since 2020, will continue as Vice Chairman of the company's board of directors.

09:24 EDT Lincoln Educational names Marta Ronquillo Newhart, Anna Escobedo Cabral to board - Lincoln Educational Services announced that Marta Ronquillo Newhart and Anna Escobedo Cabral, have been appointed to the Company's Board of Directors. Marta Ronquillo Newhart is currently serving as Independent Director, Enterprise Leader and Chief Marketing, Communications & Brand Officer at APCO Worldwide, a global advisory and advocacy firm serving as strategic advisors to some of the world's leading corporations. Anna Escobedo Cabral is currently a board member of Navient Corporation, a student loan servicer, where she serves as Chair of the Audit Committee and a member of the Nominations and Governance Committee. She has been a director there since December 2014. She previously served as Treasurer of the United States of America from 2004 to 2009.

09:22 EDT Plumas Bancorp added to Russell 2000 Index - Plumas Bancorp was included again as a member of the US small-cap Russell 2000 Index, effective after the US market opens on July 1, as part of the 2024 Russell indexes reconstitution. Membership in the Russell 2000 Index, which remains in place for one year, is based on membership in the broad-market Russell 3000 Index. The stock also was automatically included in the appropriate growth and value indexes.

09:21 EDT Purple Biotech announces exercise of warrants for $2M gross proceeds - Purple Biotech has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 5,633,509 American Depositary Shares each representing 10 ordinary shares, having original exercise prices ranging from $1.25 to $20.00 per ADS, originally issued by Purple Biotech in October 2023, June 2020, January 2019 and June 2018, at a reduced exercise price of $0.36 per ADS. The issuance and/or resale of the ADSs issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form F-3. The offering is expected to close on or about July 2, 2024, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the existing warrants for cash, the Company will issue new unregistered Series A-1 warrants to purchase up to an aggregate of 4,979,383 ADSs and new unregistered Series A-2 warrants to purchase up to an aggregate of 6,287,635 ADSs. The new warrants will be immediately exercisable at an exercise price of $0.40 per ADS. The Series A-1 warrants will have a term of five years from the issuance date and the Series A-2 warrants will have a term of twenty-four months from the issuance date. The gross proceeds to the Company from the exercise of the existing warrants are expected to be approximately $2 million, prior to deducting placement agent fees and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund the development of its oncology therapeutic candidates and for general working capital and corporate purposes.

09:19 EDT Fossil CFO Sunil Doshi to depart, Andrew Skobe named interim - Fossil Group has appointed Andrew Skobe as the Company's Interim CFO, effective immediately. Skobe assumes the CFO role from Sunil Doshi, who is leaving the Company for another opportunity. Doshi will remain with the Company through July 19, 2024 to ensure a smooth transition. The Company has initiated a search for a permanent CFO successor to Mr. Doshi. Prior to Ankura, Skobe was EVP and CFO for Radisson Hotel Group from 2017 to 2019.

09:17 EDT Synchronoss to join Russell Microcap Index - Synchronoss Technologies is set to join the Russell Microcap Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective after the US market opens today, July 1.

09:17 EDT LPL Financial: Zack Wealth Group joins Linsco by LPL Financial - LPL Financial announced that father and daughter financial advisors James Zack and Amanda Zack have joined LPL's employee advisor channel, Linsco by LPL Financial, to launch The Zack Wealth Group. They reported serving approximately $290 million in advisory, brokerage and retirement plan assets and join LPL from Morgan Stanley. Based in Washington, D.C., Jim Zack is a seasoned advisor who has always been intrigued by the stock market. He recalled reading the stock pages in the newspaper in his youth and said his fascination with numbers, coupled with his love of serving others, led to his career as a financial advisor. Amanda Zack witnessed first-hand as her father started his business, went on calls and grew his client base, building lasting relationships along the way. She followed his footsteps by joining his practice eight years ago.

09:13 EDT Artelo Biosciences presents preclinical data on ART26.12 - Artelo Biosciences announced Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12, Artelo's novel fatty acid binding protein 5 inhibitor at the 34th Annual International Cannabinoid Research Society Symposium being held June 30 to July 5, 2024 in Salamanca, Spain. The presentation entitled, "ART26.12, a Novel Fatty Acid-Binding Protein 5 Inhibitor, Shows Efficacy in Breast Cancer-Induced Bone Pain," highlights the effectiveness of ART26.12 in reducing pain behaviors induced by breast cancer in preclinical studies. This new data is from the fourth in a series of preclinical pain models that demonstrated similar activity with ART26.12. Specifically, effective doses and plasma exposures in the breast cancer bone pain study are consistent with previously published data of ART26.12 in oxaliplatin-induced peripheral neuropathy. "ART26.12 continues to deliver positive preclinical efficacy data to support its development as a novel non-opioid, non-steroidal analgesic treatment," stated Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo. "We continue to be impressed with the consistent activity and efficacious dose levels of ART26.12 in multiple animal models of pain and painful neuropathies, whether caused by cancer, diabetes, or multiple chemotherapies. We look forward to initiating human trials with ART26.12 subject to Artelo's Investigational New Drug application acceptance by the U.S. Food and Drug Administration."

09:09 EDT Wearable Devices demonstrates integration of Mudra tech with Snapdragon Spaces - Wearable Devices (WLDS) announced the completion of its first phase of integration with Qualcomm's (QCOM) Snapdragon Spaces, extended reality Developer Platform. This milestone follows the collaboration agreement announced earlier this year, marking a significant moment in the XR industry through gesture-based control. The completion of this integration stage, previously announced, enhances the capabilities of XR environments and highlights Wearable Devices' dedication to advancing the frontier of wearable technology. By leveraging the precise gesture recognition enabled by Mudra technology, the Snapdragon Spaces platform will offer users a more natural and intuitive interface, thereby elevating the overall XR experience.

09:07 EDT Mama's Creations joins Russell 2000, Russell 3000 Indexes - Mama's Creations announced that the Company's common stock was added to the Russell 2000 and Russell 3000 Indexes after the market closed on June 28, 2024.

09:06 EDT Phunware added to FTSE Russell Microcap Index - Phunware was added to the FTSE Russell Microcap Index at the conclusion of the 2024 FTSE Russell annual index reconstitution, effective after market close on June 28, 2024.

09:05 EDT Despegar added to Russell equity indexes - Despegar.com announced that, as part of the annual reconstitution of the Russell equity indexes, the company has been added to the Russell 2000 Index and the broad-market Russell 3000 Index, effective at the open of the U.S. equity markets on July 1.

09:04 EDT Arthur J. Gallagher acquires Zayla Partners - Arthur J. Gallagher & Co. announced the acquisition of Katy, Texas-based Zayla Partners. Terms of the transaction were not disclosed. Zayla is an executive compensation strategy firm that serves clients across a variety of sizes and industries. Chris Crawford, Ian Keas and their team will remain in their current locations in Texas and Colorado under the direction of Steve Coco, Global Human Resources & Compensation Consulting Managing Director for Gallagher's employee benefits consulting and brokerage operations.

09:03 EDT Oceania Cruises floats out new ship Allura - Oceania Cruises, a wholly owned subsidiary of Norwegian Cruise Line Holdings, has marked an important milestone in the construction of its new 1,200-guest ship, Allura, at the Fincantieri shipyard in Sestri Ponente, Italy, bordering the famed seaport of Genoa. A landmark moment as the ship moves towards completion, the vessel was floated from the dry-dock and moved to the fitting-out berth to begin outfitting the luxurious, designer-inspired interiors.

09:02 EDT Cassava sinks after SEC probe yields new simufilam study information - Shares of Cassava Sciences are moving lower after the company disclosed it has been engaging with the Department of Justice and Securities and Exchange Commission in connection with ongoing investigations into the company and two senior employees. Cassava is cooperating with the DOJ and SEC in connection with these investigations. In the course of ongoing discussions with the SEC regarding the company's Phase 2b study of simufilam in Alzheimer's disease, the SEC recently provided the company with new information obtained during its investigation. The company said its board "has empowered an Ad Hoc Investigation Committee: to direct an investigation of the information provided by the SEC. The internal investigation is also evaluating information contained in the DOJ indictment of Dr. Hoau-Yan Wang. Shares of Cassava are sinking 18%, or $2.20, to $10.15 in premarket trading.

09:01 EDT LQR House enters up to $6.5M agreement with Of The Earth - LQR House announces a significant advancement for its SWOL Tequila brand with a new agreement with Of The Earth Distribution Corp. for a total amount of up to $6.5 million USD. Of The Earth agreed to purchase SWOL Tequila for a total amount of up to $2 million USD. LQR House will also provide marketing services to Of The Earth for the purchased SWOL Tequila for a total amount of up to $4.5 million USD, which will depend on the number of purchased bottles. Of The Earth may choose to purchase lesser quantity of bottles and terminate the agreement if sales targets are not met. Of The Earth is given an exclusive right to distribute and sell SWOL Tequila in several provinces of Canada.

08:58 EDT Kintara Therapeutics, TuHURA provide update on corporate, clinical advancements - Kintara Therapeutics and TuHURA Biosciences provided an overview of Kintara's and TuHURA's recent corporate and clinical advancements and outlined upcoming expected near term milestones. Recent Corporate Achievements: In April 2024, Kintara and TuHURA entered into definitive merger agreement, pursuant to which Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, will merge with and into TuHURA, with TuHURA surviving the merger and becoming Kintara's direct, wholly-owned subsidiary. The Merger is expected to close in the third quarter of 2024. Kintara's existing stockholders will own approximately 5.5% of combined company's common stock at the closing of the Merger, inclusive of the contingent value right linked to the achievement of enrollment of a minimum of 10 patients in the REM-001 study, with such patients each completing 8 weeks of follow-up on or before December 31, 2025. TuHURA to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda in first-line treatment for advanced Merkel cell carcinoma in the second half of 2024 under FDA's accelerated approval pathway. TuHURA's first-in-class bifunctional Antibody Drug Conjugates represent potential upside partnering opportunities. $31 million subscribed financing by TuHURA in connection with the Merger Agreement expected to provide cash runway into late 2025. On June 12, 2024, Kintara received a 180-day extension until December 9, 2024 from The Nasdaq Stock Market LLC to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). Recent Clinical Advancements: Advanced enrollment, dosing and clinical site expansion in Kintara's open label 15-patient REM-001 study in cutaneous metastatic breast cancer. As of June 26, 2024, four patients have been dosed in the open label 15-patient REM-001 study in CMBC. In addition to Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, the University Hospital for Albert Einstein College of Medicine, will soon begin screening patients. The majority of the costs to run this study will be covered by the $2.0 million Small Business Innovation Research grant Kintara was awarded from the National Institutes of Health. In March 2024, Kintara expanded inclusion criteria in the open label 15-patient REM-001 study in CMBC to include patients receiving pembrolizumab for at least three months at screening. This is expected to significantly increase the pace of enrollment. Expected Near-term Milestones: Q3 2024: Close Merger with TuHURA. Q4 2024: Complete enrollment and 8 week follow-up of 10 patients in the REM-001 study. 2H 2024: Commence TuHURA's Phase 3 trial for IFx-2.0 personalized cancer vaccine for advanced Merkel cell carcinoma under FDA's accelerated approval pathway.

08:57 EDT Genentech treatment of hemophilia A granted FDA orphan status - Genentech, a member of the Roche Group, was granted FDA orphan designation for a treatment of hemophilia A, according to a post to the agency's website. Reference Link

08:57 EDT Toro Australia sells residential Pope Products business, no terms - The Toro Company (TTC), through its wholly-owned subsidiaries Toro Australia and Toro Australia Group Sales based in South Australia announced the sale of its Pope Products residential garden watering and irrigation business to The AMES Company, , a subsidiary of Griffon Corporation (GFF). Pope irrigation and garden watering products are sold exclusively in Australia and New Zealand. This transaction represents The Toro Company's commitment to disciplined portfolio management and prudent capital allocation strategies. The transaction also represents an opportunity for Toro Australia to enhance its focus on the best opportunities to drive long-term profitable growth in the golf, sports fields and grounds, professional contractor, rental and residential markets. The financial results related to the Pope Products business have historically been included in the company's residential segment results. The impact of this divestiture is immaterial to the company's fiscal 2024 financial results and was already considered in the previously shared outlook for the third quarter and full-year.

08:55 EDT ChromaDex to be included in Russell 2000 Index - ChromaDex announced its inclusion in the Russell 2000 Index as part of the annual reconstitution of the Russell stock indexes. This inclusion will be effective at the opening of U.S. equity markets on Monday, July 1, based on the preliminary list of additions posted on Friday, May 24.

08:54 EDT Collective Audience closes acquisition of DSL Digital - Collective Audience has completed its acquisition of DSL Digital, a provider of Marketing-as-a-Service solutions powered by proprietary AI technology. Collective Audience acquired a controlling 51% interest in DSL Digital, with an exclusive option to acquire the remaining 49% within the next two years.The acquisition will form the foundation for Collective Audience's new AudienceServices group, with multi-million-dollar profitable revenues growing at 20% annually. Collective Audience expects to recognize substantial revenue growth from the acquisition and AudienceServices in the second quarter and accelerating for the rest of 2024.

08:50 EDT Kintara Therapeutics, TuHURA provide update on recent advancements - Kintara Therapeutics provided an overview of Kintara's and TuHURA's recent corporate and clinical advancements and outlined upcoming expected near term milestones. In April 2024, Kintara and TuHURA entered into definitive merger agreement, pursuant to which Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, will merge with and into TuHURA, with TuHURA surviving the merger and becoming Kintara's direct, wholly-owned subsidiary. The Merger is expected to close in the third quarter of 2024. On June 12, 2024, Kintara received a 180-day extension until December 9, 2024 from The Nasdaq Stock Market LLC to regain compliance. Expected Near-term Milestones: Q3 2024: Close Merger with TuHURA. Q4 2024: Complete enrollment and 8 week follow-up of 10 patients in the REM-001 study. 2H 2024: Commence TuHURA's Phase 3 trial for IFx-2.0 personalized cancer vaccine for advanced Merkel cell carcinoma under FDA's accelerated approval pathway.

08:49 EDT Geo, Oklahoma reached one-year contract for Lawton facility (last week) - Geo Group and the Oklahoma Department of Corrections have worked together on a one-year contract to continue operating the Lawton Correctional and Rehabilitation Facility, the agency announced last Wednesday. An agreement was reached on the terms of a new one-year contract, effective July 1, 2024. "This does not mean the facility will return to the status quo," explained ODOC Director Steven Harpe. "We are putting more procedures in place to ensure safety for our incarcerated population." As part of the agreement, ODOC will reduce the number of inmates housed at LCRF. With the population reduction, GEO "has pledged to actively work to reduce violence, provide more access to programs, and grant more out-of-cell time for the inmates," the agency said in last week's statement. The facility currently houses 2,616 inmates, including the state's only protective custody unit. The Board of Correction approval allows the contract to move forward in the process to be approved by the Attorney General's office and executed by ODOC. Reference Link

08:48 EDT Prenetics appoints Kathryn Henry, David Vanderveen to board - Prenetics Global welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. Henry previously served as Chief Information Officer, Logistics & Distribution at Lululemon from 2010 to 2014, where she oversaw all global information and technology operations for the company. From 2022 until recently, Vanderveen was CEO of Nirvana Water Sciences.

08:45 EDT Orrstown Financial, Codorus Valley Bancorp complete merger - Orrstown Financial Services, Inc. (ORRF), and Codorus Valley Bancorp, Inc. (CVLY), announced the completion of their previously announced merger of equals creating a premier Pennsylvania and Maryland community bank. The combined company will trade on the Nasdaq Global Select Market under the Orrstown ticker symbol "ORRF" and operate under the "Orrstown Financial Services, Inc." name. The combined bank will operate under the "Orrstown Bank" name once the systems and services of Orrstown Bank and PeoplesBank are combined, which is expected in November 2024. Until then, PeoplesBank will continue to serve its clients and conduct its business under the PeoplesBank brand name, while operating as a division of Orrstown Bank. The administrative headquarters of the combined company will be located in Harrisburg, PA, and the operations center of the combined company will be located in York, PA. At the effective time of the merger on July 1, 2024, each outstanding share of Codorus Valley common stock was converted into the right to receive 0.875 shares of Orrstown common stock. Former Codorus Valley shareholders collectively represent approximately 44% of the combined company. Shares of Codorus Valley common stock ceased trading prior to the opening of the NASDAQ Global Market Stock Market on July 1, 2024.

08:42 EDT Nano Nuclear Energy, CURIO collaborate on advanced nuclear fuel recycling - NANO Nuclear Energy has signed a Memorandum of Understanding to collaborate with Curio Solutions to optimize Curio's nuclear fuel recycling capabilities for NANO Nuclear's next-generation portable nuclear microreactors in development. This MOU marks another achievement in NANO Nuclear's commitment to explore and assemble complimentary advanced technologies to further enable the development of its 'ZEUS' and 'ODIN' microreactors. Based in Washington, D.C., Curio Solutions is a leading advanced nuclear recycling technology developer and pioneer of the NuCycle process. Utilizing chemistries that increase operational modularity, capacity, and economic viability, NuCycle offers a recycling opportunity to dramatically reducing nuclear waste. The companies will now collaborate for one year and seek to optimize NANO Nuclear's fuel designs for enhanced recyclability and seek to implement cutting edge recycling methods utilizing the NuCycle process. The collaboration will also explore opportunities to integrate recycled fuel into NANO Nuclear's advanced microreactor designs. The MOU is preliminary, but if the collaboration evolves as expected, the companies would ultimately seek enter into more formal definitive documentation.

08:40 EDT Reliance Global forms new Real Estate division aimed at expanding operations - Reliance Global Group announced the formation of a new Real Estate division drawing on Ezra Beyman's extensive background in building the third-largest mortgage brokerage in the nation and accumulating a multi-billion-dollar portfolio of multi-family properties. Furthermore, Abe Miller, successful real estate investor and M&A executive, has agreed to join Reliance to oversee this new division and advise on future real estate transactions. Mr. Miller will receive no fixed salary for his services; rather, he will be compensated entirely on a success-based model. The new division is intended to supplement, and not replace, the Company's focus on acquiring accretive and cash flow positive insurance agencies.

08:38 EDT Ascendent Capital says obtained all needed PRC approvals for Hollysys deal - In a regulatory filing, Ascendent Capital Partners announced that its affiliate, Superior Technologies Holding Limited, or the "Buyer," has obtained all the PRC approvals that the Buyer is required to obtain for the Buyer to complete the Merger with Hollysys. "Ascendent Capital Partners is working to complete the Merger expeditiously," the filing stated. Reference Link

08:38 EDT Ametek appoints Kowalski as VP, General Manager, AMS Division - AMETEK announced the appointment of Keith Kowalski as Vice President, VP, and General Manager, Advanced Motion Solutions, AMS, Division. Kowalski previously served as Divisional Vice President and Business Unit Manager for the Precitech TMC business within AMETEK's Ultra Precision Technologies division.

08:36 EDT Eightco Holdings granted continued listing on Nasdaq Capital Market - Eightco Holdings announced that a Hearings Panel of the Nasdaq Stock Market has granted the Company's request for continued listing on The Nasdaq Capital Market, subject to the Company meeting certain conditions by August 23, 2024. These conditions include requiring the closing bid price of the Company's common stock to equal or exceed $1.00 per share for a minimum of ten consecutive trading sessions. In order to meet the conditions required by the Hearings Panel, the Company has filed a preliminary proxy statement with the Securities and Exchange Commission seeking shareholder approval to effect a reverse stock split of all of the outstanding shares of the Company's common stock at a ratio of 1-for-5.

08:35 EDT Foxo Technologies regains compliance with SEC reporting requirements - FOXO Technologies has filed its Form 10-Q for the quarter ended March, 31, 2024 and in doing so has regained compliance with SEC reporting requirements. The Company closed the previously announces Myrtle transaction on June 14, 2024 and simultaneously secured a commitment for up to $2.5M of additional capital. Myrtle Recovery Centers, Inc. is a 30 bed behavioral health facility in East Tennessee. It provides inpatient services for Detox and Residential Treatment and outpatient services for MAT and OBOT Programs. The facility was opened in August 2023 and has secured an in-network contract with one of the major health insurance companies in Tennessee and is in the final stages of securing various other in-network contracts to facilitate payment for services. The Company anticipates this transaction will provide profitable annual revenues of approximately $3-4M with plans to grow revenues and duplicate the model in different locations. Closing of the previously announced Scott Country transaction to acquire a rural hospital remains subject to a shareholder vote and other conditions and is expected to close in the third quarter of 2024.

08:33 EDT TH International announces financing from founding shareholders - TH International Limited (THCH) secured an aggregate of up to $65 million of financing and additional funding from its founding shareholders, Cartesian Capital Group and Restaurant Brands International (QSR). The financing includes $50 million in convertible notes, of which $40 million was issued at closing, with the balance to be funded over the coming 7 months, subject in each case to certain conditions. The three-year notes are convertible into newly issued convertible preferred shares of Tims China, which convert to ordinary shares at a price per share based on 110% of the VWAP for the 5 trading days immediately prior to closing of the transaction. In addition, through one of its foreign entities, RBI has acquired the Popeyes China business from Tims China on a cash-free debt-free basis for an enterprise value of $15 million. Simultaneously, Tims China has extinguished the deferred consideration due to former shareholders of Popeyes China via issuance of a $15 million convertible note, which converts directly into ordinary shares with financial terms similar to those outlined above.

08:31 EDT Evolus appoints Albert White to board of directors - Evolus announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aesthetics company to a multi-product performance beauty innovator. His expertise will help Evolus further its strategy and aid in our focus on delivering long-term shareholder value."

08:29 EDT GCT Semiconductor announces addition to Russell 3000 Index July 1 - GCT Semiconductor announced its addition to the Russell 3000 Index as part of the annual Russell reconstitution, effective as of the open of US equity market today on July 1.

08:28 EDT Perfect Corp. announces collaboration with NAO-ART - Perfect Corp. announced its collaboration with NAO-ART, a subsidiary of the Art Nature Group and a provider of ready-to-wear wig brands for women. Perfect Corp. will provide NAO-ART with a virtual try-on tool for wigs utilizing generative AI technology. The target items include 53 wigs, including fashion wigs and medical wigs.

08:27 EDT Neuronetics launches Better Me Provider program nationwide - Neuronetics announced the national launch of the Better Me Provider program, pioneering new standards in patient care and responsiveness to improve treatment accessibility within the mental health industry. The providers participating in the program are committed to rigorous standards, developed in collaboration with a network of TMS medical experts. The BMP program, a comprehensive commercial initiative, is nationally available today where NeuroStar Practice Development Managers will continue to collaborate with NeuroStar practices to help them meet the qualifying criteria and enroll in the program. There are currently 300 active sites in the program, with over 125 more committed to adhering to the standards in anticipation of the national rollout in July.

08:25 EDT G1 Therapeutics added to Russell 2000, 3000 Indexes - G1 Therapeutics announced that the Company has been added to the broad-market Russell 3000 and small-cap Russell 2000 Indexes as of the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, July 1, 2024.

08:24 EDT Solid Biosciences joins Russell 3000 Index - Solid Biosciences announced that the Company has been added to the broad-market Russell 3000 Index as part of the annual reconstitution, effective at the open of US equity markets today, Monday, July 1st 2024.

08:22 EDT AI Transportation, American Metals execute business combination agreement - American Resources Corporation's (AREC) American Metals and AI Transportation Acquisition Corp (AITR) announced that American Metals and AITR have executed a definitive business combination agreement for a proposed business combination in a transaction valued at $170,000,000. Pursuant to the Business Combination Agreement, each of AITR and American Metals will become wholly-owned subsidiaries of a newly formed Delaware corporation, Electrified Materials Corporation, which will serve as the parent company of AITR and American Metals following the consummation of the Business Combination. It is anticipated that the combined company will be listed on the Nasdaq Stock Market under the ticker symbol "EMCO." American Metals is a cutting-edge recycler of metals to the electrified economy and processor of used metals and minerals to be recycled and further refined into new steel-based, battery-grade and magnet-grade products. Today, American Metals operates within the U.S. with its origins being the reclamation of former thermal coal mines. By leveraging its regional logistics and infrastructure as well as its knowledge and affiliation with ReElement Technologies Corporation, an industry-leading refining technology platform, American Metals expects to expand its presence in the high-growth market of used steel, rare-earth elements, battery materials while also cleaning up old infrastructure left behind from the declining mining industry. The exploding demand for these metals worldwide is expected to result in an undersupply, threatening the realization of the energy transition. Despite their scarcity, the recycling rate for many critical metals is below 5%, with total recycled metals in batteries currently around 1%, and recycling rate of certain rare earths even below 1%, according to the World Economic Forum's April 24, 2024 report.1 American Metals is uniquely positioned to be a leading producer of critical metals while contributing to a reduction in global greenhouse gases. Importantly, American Metals has also established a complete closed-loop supply chain for such materials through its non-exclusive partnership with ReElement to refine such material to battery and magnet grade. The completion of the Business Combination is subject to regulatory approvals, the approval of the transaction by the shareholders of AITR and American Metals, and the satisfaction or waiver of other customary closing conditions. Throughout the Business Combination, AITR will endeavor to support American Metals' business growth to strengthen American Metals' position in the high-growth market of used steel and rare-earth metals markets. American Metals believes that its planned listing, in addition to creating a capital platform for its development and gaining the attention of investors in the international capital markets, will further promote American Metals' growth strategy.

08:20 EDT BlackRock to acquire Preqin for $3.2B in cash - BlackRock has agreed to acquire Preqin, an independent provider of private markets data, for GBP 2.55B or approximately $3.2B in cash. "Bringing together Preqin's data and research tools with Aladdin's complementary workflow capabilities in a unified platform will create a preeminent private markets technology and data provider. The acquisition adds a highly complementary data business to BlackRock's investment technology, marking a strategic expansion into the fast-growing private markets data segment. Private markets are the fastest growing segment of asset management, with alternative assets expected to reach nearly $40 trillion by the end of the decade. As institutional and wealth investors increase allocations to alternatives, BlackRock has built a leading private markets franchise to meet this client demand. There is an even greater need for standardized data, benchmarks, and analytics that enable investors to better incorporate private asset classes into portfolios and provide fund managers with better data and tools to deliver outcomes for clients. Private markets data is estimated to be an $8 billion total addressable market and growing 12% per year, reaching $18 billion by 2030. Preqin empowers investors to make better decisions by providing data and insights that increase transparency and access across the global alternatives market. With a 20-year history, Preqin is a leading independent data solutions provider in private markets with global coverage of 190,000 funds, 60,000 fund managers and 30,000 private markets investors, reaching more than 200,000 users, including asset managers, insurers, pensions, wealth managers, banks, and other service providers. In 2024, Preqin is expected to generate ~$240 million of highly recurring revenue and has grown approximately 20% per year in the last three years. Through the Aladdin platform, BlackRock provides technology solutions to over 1,000 clients. The combination of Preqin with eFront, Aladdin's private markets solution, brings together the data, research, and investment process for fund managers and investors across fundraising, deal sourcing, portfolio management, accounting, and performance. Preqin will also continue to be offered as a standalone solution," the company stated. The transaction is expected to close before year-end 2024, subject to regulatory approvals and other customary closing conditions.

08:18 EDT Merus appoints Fabian Zohren as CMO - Merus announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In addition, effective July 1, Hui Liu, Ph.D., EVP, Chief Business Officer & Head of Merus U.S. is leaving Merus. The Company has initiated a search to find a replacement to head the business development function. Zohren joins Merus from ImmunoGen where he was SVP and Chief Medical Officer from November 2023 through its acquisition by AbbVie in May 2024.

08:17 EDT Tonix Pharmaceuticals awarded up to $34M U.S. DoD contract - Tonix Pharmaceuticals has been awarded an Other Transaction Agreement with a potential for up to $34 million over five years by the Defense Threat Reduction Agency, an agency within the U.S. Department of Defense. The objective of the contract is to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix's program will focus on optimization and development of its TNX-4200 program, to develop an orally available CD45 antagonist, with broad-spectrum efficacy against a range of viral families through preclinical evaluation. The program is expected to establish physicochemical properties, pharmacokinetics, and safety attributes to support an Investigational New Drug submission and to fund a first-in-human Phase 1 clinical study.

08:14 EDT Enphase Energy releases Solargraf platform in the Netherlands - Enphase Energy announced that Solargraf, its cloud-based design and proposal software platform, is now available in the Netherlands. The software is currently being used for both residential and commercial projects by solar installers in the United States, Canada, Brazil, Germany, and Austria.

08:14 EDT Cassava Sciences says cooperating with DOJ, SEC investigations - In an update on government investigations shared in a regulatory filing, Cassava Sciences stated: "Cassava Sciences, Inc. has been engaging with the U.S. Department of Justice and the U.S. Securities and Exchange Commission in connection with ongoing investigations into the Company and two senior employees of the Company. Cassava is cooperating with the DOJ and SEC in connection with these investigations. In the course of ongoing discussions with the SEC regarding the Company's Phase 2b study of simufilam in Alzheimer's disease, the SEC recently provided the Company with new information obtained during its investigation. The Company's Board of Directors has empowered an Ad Hoc Investigation Committee, comprising independent directors, to direct an investigation of the information provided by the SEC. The Internal Investigation is also evaluating information contained in the DOJ indictment of Dr. Hoau-Yan Wang discussed below. This Committee, with the assistance of the Company's General Counsel, is supervising outside counsel conducting the Internal Investigation. The Committee is also empowered to oversee the Company's disclosures in filings with the SEC regarding matters at issue in the Internal Investigation. The Internal Investigation is continuing... Based on the Committee's preliminary review of information gathered in the Internal Investigation to date, the Company is supplementing its prior disclosures, initially reported in September 2020, regarding the Phase 2b Study. The Phase 2b Study was designed as a 28-day, approximately 60-patient, randomized, double-blind, placebo-controlled, multiple dose study. One objective of the Phase 2b Study was to measure changes in levels of cerebrospinal fluid biomarkers in study participants from baseline value to Day 28. Based on CSF biomarker assays and bioanalysis conducted by Dr. Wang, Cassava reported statistically significant improvements in biomarkers in treatment groups as compared to the placebo group. To date, the Internal Investigation has determined that certain statistical information contained in an attachment to an email sent by a senior employee of Cassava to Dr. Wang before the bioanalysis could have been used to unblind him as to some number of Phase 2b Study participants. Another objective of the Phase 2b Study was to measure changes in cognitive outcome measures using the Cambridge Neuropsychological Test Automated Battery, or CANTAB, (a validated, computer-based battery of tests) over the 28-day study period. Neither Dr. Wang nor his laboratory at CUNY was involved in the cognition portion of the Phase 2b Study. With respect to the cognition portion of the Phase 2b Study, Cassava is reporting in this 8-K information regarding its post hoc statistical analysis with respect to selected CANTAB outcome measures for the Phase 2b Study. This information was previously disclosed in a draft preprint manuscript that was publicly available as of the first quarter of 2021. The Phase 2b Study's CANTAB tests were not powered for statistical significance and were therefore evaluated only for effect size. In September 2020, the Company reported on study participants' episodic memory and spatial working memory, as assessed using CANTAB, over the 28-day study period. The Company reported the primary outcome measurements of Paired Associates Learning total errors adjusted, in respect of episodic memory, and total errors in respect of Spatial Working Memory. Other outcome measurements that were generated by the CANTAB tests were not reported by the Company. Although the 28-day Phase 2b Study enrolled 64 patients, the statistical analysis of the CANTAB outcome measurements reported by the Company reflected certain study participant exclusions. With respect to the analysis of episodic memory measures, approximately 42% of study participants were excluded from the reported analysis. For these episodic memory test exclusions, the most and least impaired subjects were excluded by baseline score before the effect size was calculated. These cutoffs were employed to remove subjects with very few errors, as well as subjects who performed so poorly that they may not have understood the task evaluated by the test. Analysis of both CANTAB test data sets also excluded subjects with no detectable plasma simufilam, patients who were greater than or equal to25% noncompliant with the study's treatment regimen by pill counts, patients with no baseline test, and patients who, according to study investigators, did not understand the test instructions. Accordingly, reported results reflected N=14, 13, 10 for episodic memory, and N=22, 17, 18 for spatial working memory for placebo, 50 and 100 mg, respectively. Because the results first reported in September 2020 reflect calculations of effect size after these exclusions, the Company's reported results reflect an analysis of a substantially smaller analysis-set population than the full Phase 2b Study population... The Company is currently conducting two randomized, placebo-controlled Phase 3 clinical trials of oral simufilam in patients with mild-to-moderate Alzheimer's disease. Both trials are fully enrolled. The trials have randomized a total of approximately 1,900 patients with mild-to-moderate Alzheimer's disease at baseline. All efficacy data from the Company's Phase 3 program remain blinded. There are no interim analyses on efficacy outcomes. Phase 3 data and samples for bioanalysis will be directly provided to and analyzed by independent, third-party commercial consulting firms. Neither Dr. Wang nor his laboratory at CUNY has any involvement in the Company's ongoing Phase 3 clinical trials of simufilam." Reference Link

08:12 EDT New Fortress Energy to sell liquefaction, storage facility in Miami - New Fortress Energy announced that it has entered into a definitive agreement to sell its liquefaction and storage facility in Miami, Florida to a U.S. middle-market infrastructure fund. The transaction is expected to close in the third quarter of 2024 subject to customary terms and conditions. The Miami Facility is a small-scale liquefaction facility with one liquefaction train capable of producing 8,300 MMBtu of LNG per day. The facility has three LNG storage tanks with a total capacity of approximately 1,000 cubic meters as well as two separate LNG transfer areas capable of serving both truck and rail. The facility is authorized to export up to 60,000 tons per annum of LNG to Free Trade Agreement and Non-FTA countries for a 20-year term that began on February 5, 2016.

08:11 EDT Lifecore enters cooperation agreement with 22NW - Lifecore Biomedical has reached a cooperation agreement with 22NW, which provides for the addition of Humberto Antunes, Jason Aryeh, Paul Johnson and Matthew Korenberg to the Board of Directors of the Company effective immediately following the 2023 Annual Meeting of Stockholders. The Agreement includes the following key terms: 22NW will withdraw its notice of nominations of director candidates at the 2023 Annual Meeting, as well as its demand for a special meeting of stockholders to vote on an advisory proposal to declassify the Board. Nathaniel Calloway, a partner at 22NW, will resign as one of the two Series A Board designees immediately prior to the 2023 Annual Meeting. Humberto Antunes, Jason Aryeh, Paul Johnson and Matthew Korenberg will join as Board observers within 10 days of the execution of the Agreement. Messrs. Antunes, Johnson and Korenberg will be appointed as directors immediately following the 2023 Annual Meeting and Mr. Aryeh will be added to the slate of the Company's nominees for election at the 2023 Annual Meeting as a Series A Board designee. Mr. Korenberg will be appointed as a member of the Audit Committee and Mr. Aryeh will be appointed as a member of the Nominating and Corporate Governance Committee, in each case subject to availability and satisfaction of the required qualifications. If a vacancy were to occur in the role of the Chairperson of the Audit Committee in the future, Mr. Korenberg will also be appointed to such role, subject to availability and satisfaction of the required qualifications. Following Mr. Barbarosh's previously announced determination to resign on or before the 2023 Annual Meeting, the size of the Board will be reduced from nine to eight seats immediately prior to the 2023 Annual Meeting, then will increase from eight seats to 11 seats immediately following the 2023 Annual Meeting, and, finally, will be reduced from 11 to nine seats as of the earlier of the 2024 Annual Meeting of Stockholders or November 30, 2024. The Board will recommend the 22NW proposal to be voted on at the 2023 Annual Meeting to provide for the declassification of the Board, resulting in one-year terms for all directors beginning at the Company's 2025 Annual Meeting of Stockholders. This proposal is the result of the Board's continued evaluation of the Company's corporate governance practices. 22NW has signed a standstill and support agreement lasting through the 2025 Annual Meeting. Large stockholders Legion Partners Asset Management, LLC and Wynnefield Capital, Inc., and their respective affiliates, have entered into similar support agreements.

08:10 EDT Avantor launches J.T.Baker Cell Lysis Solution, J.T.Baker Endonuclease - Avantor announced the launch of two products that together sustainably optimize the gene therapy harvest process: J.T.Baker Cell Lysis Solution and J.T.Baker Endonuclease.

08:09 EDT Biora Therapeutics announces clinical trial results for BT-600 - Biora Therapeutics shared topline results from its clinical trial of BT-600, an orally administered drug-device combination in development for the potential treatment of patients with ulcerative colitis. BT-600 leverages Biora's ingestible NaviCap device to deliver a proprietary liquid formulation of tofacitinib directly to the colon. Results from this Phase 1 clinical trial involving 48 healthy volunteers met all trial objectives, with demonstrated drug absorption in colonic tissue that extended to the distal colon, suggesting pan-colonic delivery. Daily dosing with BT-600 was well tolerated by all participants. Results from the Phase 1 clinical trial demonstrate a pharmacokinetic profile consistent with drug delivery and absorption in the colon for both single and multiple ascending dose cohorts. First evidence of systemic absorption of tofacitinib was at six hours, consistent with colonic delivery. Maximal levels in the trial occurred at eight to ten hours vs. 30 minutes for conventional oral tofacitinib in other trials. Maximal systemic drug exposure was three to four times lower than that seen with conventional oral tofacitinib in other trials, demonstrating the NaviCap platform's ability to deliver locally to the colon and limit systemic drug exposure. The distribution of colon tissue exposure suggests that pan-colonic delivery of tofacitinib was achieved. Sites in the distal colon were biopsied, following delivery of tofacitinib in the proximal colon, for evidence of tissue drug exposure. Biopsy results provided evidence of drug exposure extending to the distal colon, at common sites of disease. Post-retrieval device analysis further confirmed that NaviCap devices accurately delivered drug in the colon, with 100% of devices and 98% of devices detecting colon entry. NaviCap devices were well tolerated by participants in both the SAD and MAD cohorts.

08:09 EDT Amneal Pharmaceuticals licenses ADL018 to Kashiv BioSciences - Kashiv BioSciences announced that it has entered into an exclusive licensing agreement for ADL018, a proposed biosimilar to omalizumab referencing Xolair, with Amneal Pharmaceuticals for the United States. Omalizumab, which targets free IgE, is a humanized monoclonal antibody. It is an injectable prescription drug used to treat a number of chronic conditions such as severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps, food allergies, and chronic spontaneous urticaria, and is typically administered in a hospital or clinic setting. The biosimilar was developed by Kashiv BioSciences, and is currently in a Phase III clinical trial, which began in the third quarter of 2023.

08:08 EDT Heidelberg Materials acquires all assets of Aaron Materials, terms not disclosed - Heidelberg Materials North America announced today that it has acquired all assets of Aaron Materials, an established concrete recycler and materials producer in the Corpus Christi area. The operations include concrete crushing, stabilized materials and a volumetric concrete business. This recent acquisition is aligned with the company's strategic focus on optimizing its portfolio in core markets and strengthening its existing businesses through bolt-on acquisitions while advancing its focus on sustainable and circular products.

08:07 EDT Korro Bio joins Russell 2000, Russell 3000, Russell Microcap Indexes - Korro Bio has been added to the Russell 2000, Russell 3000, and the Russell Microcap Indexes as part of the annual reconstitution, effective at the open of US equity markets today, Monday, July 1.

08:06 EDT Federal Court allows Vanda's HETLIOZ patent lawsuit to proceed - Vanda Pharmaceuticals (VNDA) announced that the U.S. District Court for the District of Delaware denied the motions for judgment on the pleadings that were filed by Teva Pharmaceuticals USA (TEVA) and Apotex and Apotex and ordered that Vanda's HETLIOZ patent lawsuit may proceed. Vanda brought this suit in December 2022, alleging patent infringement against Teva and Apotex. Vanda intends to proceed with discovery in the case to continue pursuing its claims. Vanda will request relief from the Court that includes an order requiring the Defendants to discontinue marketing their generic versions of HETLIOZ until the expiration of the patent-in-suit and enjoining them from the commercial manufacture, use, import, offer for sale and/or sale of these products.

08:06 EDT Booz Allen awarded $419M technology modernization contract - Booz Allen announced it was awarded a seven-year, $419M contract with the National Science Foundation, or NSF, for Information Technology Mission Application Support, or ITMAS. With this recompete win, Booz Allen will directly support the modernization and IT operations of the agency's merit review and grants management system that facilitates critical investments in scientific research-building on Booz Allen's expertise in managing complex technical mission stacks for the good of the citizen.

08:05 EDT Trulieve Cannabis to open Florida medical cannabis dispensaries - Trulieve Cannabis announced the opening of new medical cannabis dispensaries in Madison and Panama City, Florida.

08:04 EDT Inovio announced it was added to the Russell 2000 Index - INOVIO announced its inclusion in the Russell 2000 Index as part of the annual reconstitution of the Russell stock indexes. This reconstitution became effective after the close of the US equities markets on June 28, 2024.

08:04 EDT CalciMedica set to join Russell Microcap Index - CalciMedica announced that the Company is set to join the Russell Microcap Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, 2024, according to preliminary lists of additions posted on Friday, May 24, 2024.

08:03 EDT Infinera expands partnership with APRESIA Systems - Infinera is expanding its partnership with APRESIA Systems through the integration of Infinera's software-programmable ICE-X coherent pluggables into APRESIA's portfolio of locally manufactured Layer 2/3 switching and optical transmission products. Infinera's ICE-X coherent pluggables will enable APRESIA to enhance its access network solutions and offer its customers increased operational value, including new revenue-generating services, reduced CapEx and OpEx, and maximized utilization of fiber assets. APRESIA will leverage the XR optics-enabled capabilities of Infinera's ICE-X pluggables to address a broader set of access network applications. With this integration, APRESIA will initially target high-speed point-to-point and 100G bidirectional transport applications and offer its telecommunications service providers and cable operator customers the ability to cost-effectively extend the reach of high-speed optical services using Infinera ICE-X's unique digital subcarrier technology. APRESIA plans to extend ICE-X application support to include point-to-multipoint functionality, enabling significant improvement in network efficiency, reducing CapEx and OpEx by as much as 70 percent.

08:02 EDT Arteris joins Russell 2000 Index - Arteris has joined the broad-market Russell 2000 Index.

07:54 EDT LL Flooring warns its projected level of liquidity may not be sufficient - In a regulatory filing on Friday, the company stated: "As previously disclosed in the Quarterly Report on Form 10-Q filed by LL Flooring Holdings, Inc. for the quarter ending March 31, 2024, the Company, in an effort to improve its liquidity, began a process to pursue a sale transaction for its Sandston, Virginia distribution center. The Company has received a number of preliminary bids and several second-round bids in connection with such sale process and expects to move forward with negotiating with certain bidders for the possible sale of the Distribution Center. There can be no assurance that the Company will enter into a sale transaction relating to the Distribution Center, or if a transaction is entered into, the terms thereof. Under the terms of the Company's asset-backed revolving facility credit agreement (the "Credit Agreement"), the Company now believes that its projected levels of liquidity may not be sufficient to meet the minimum excess availability threshold in the third quarter of 2024. The Company is in discussions with representatives of the banks that are party to the Credit Agreement regarding an additional liquidity reserve requested by the banks and additional modifications to certain provisions of the Credit Agreement. There can be no assurance that the Company will reach an agreement with the banks regarding such matters."

07:49 EDT Biomerica launches at-home sample collection for inFoods IBS test - Biomerica announced an enhancement to its inFoods IBS system, aimed at simplifying and transforming the patient experience. The inFoods IBS diagnostic test has made a significant advancement with the introduction of a new patient self-collection system. This innovative system utilizes a simple, minimally invasive finger-stick device that enables patients to collect their own blood samples at home, bypassing the need to visit healthcare facilities. This enhancement enables the inFoods IBS product to be marketed and provided nationally through telehealth and online medical providers, significantly expanding access to millions of IBS sufferers who may not live near a GI physician offering the product. The Company believes this could have a significant positive impact on inFoods IBS revenues by reaching a broader patient population.

07:40 EDT Marti Technologies announces ride-hailing service reaches over 1.1M drivers - Marti Technologies announced that as of June 30, Marti's ride-hailing service has reached over 1,100,000 riders and over 170,000 registered drivers, exceeding the June 30 targets of over 1,000,000 riders and 165,000 registered drivers. Marti's number of ride-hailing riders grew 121% from December 31, 2023 to June 30. The number of registered drivers grew 60% during the same time period. The fast growth in both the rider and driver sides of Marti's ride-hailing marketplace demonstrates the strong need for the service across Turkiye. The service intends to provide readily available, safe, and affordable rides for riders, while providing economic opportunities for drivers across the income spectrum. Encouraged by the growth in the rider and driver bases of its ride-hailing business, Marti has set targets for over 1,300,000 riders and over 190,000 registered drivers by September 30.

07:39 EDT Neurogene to be added to Russell 3000 Index July 1 - Neurogene announced that Neurogene will be added to the Russell 3000 Index, effective at the open of U.S. equity markets today, Monday, July 1. The annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30, 2024, ranking them by total market capitalization. Neurogene's membership in the U.S. all-cap Russell 3000(R) Index will remain in place for one year. Neurogene has also been added to the Russell 2000(R) Index and the Russell Microcap(R) Index.

07:37 EDT Neurocrine announces FDA accepted two NDAs - Neurocrine Biosciences announced the U.S. Food and Drug Administration, FDA, has accepted its two New Drug Applications , NDA, with Priority Review designations for crinecerfont in the treatment of children, adolescents and adults with classic congenital adrenal hyperplasia, CAH. If approved, crinecerfont would be the first new treatment option for CAH in 70 years and a first-in-class therapy, with a novel approach for the treatment of this rare and serious endocrine disorder. The submitted crinecerfont NDAs included: the primary presentation of efficacy and safety of crinecerfont for the treatment of classic CAH as a capsule formulation; and as an oral solution formulation. The agency set Prescription Drug User Fee target action dates of December 29 and December 30, 2024, respectively.

07:35 EDT Dragonfly provides liftgate power solutions for Refreshment Services Pepsi - Dragonfly Energy Holdings is now a provider of lithium based liftgate power solutions for Refreshment Services Pepsi, a privately-held independent bottler and distributor for Pepsi-Cola products. With distribution centers across the U.S., Refreshment Services Pepsi will begin integrating the Company's Battle Born Batteries products into their fleet to power liftgate operations. This shift to lithium-ion technology will offer Refreshment Services Pepsi significant cost savings and environmental advantages compared to lead-acid batteries traditionally used in this application.

07:34 EDT Nayax launches EV CloudPay payments solution - Nayax announced the launch of Nayax EV CloudPay, a cloud-based payments solution to help consumers facilitate payments at electric vehicle charging stations. EV CloudPay allows drivers to pay for their charge with a credit card, debit card or mobile wallet via a physical payment processing kiosk that is located on-site at the charging station. Individual payment processing devices do not need to be attached to each charger. The kiosk will be able to accept more than 80 forms of cashless and digital payment methods.

07:32 EDT Bombardier announces settlement of New York bondholder lawsuit - Bombardier has reached an agreement to settle the lawsuit titled Antara Capital Master Fund LP, Corbin ERISA Opportunity Fund Ltd. and Corbin Opportunity Fund, L.P. v. Bombardier. The Lawsuit is pending in New York State Supreme Court, Commercial Division New York County since it was filed in January 2022. The settlement will become effective following satisfaction of customary conditions which may take a few days. The settlement resolves the Lawsuit completely and avoids the distraction, expenses and uncertainty associated with any litigation. All defendants will be fully released without any admission of liability. The settlement also contains a consent from plaintiffs, as beneficial holders of outstanding 7.45% Senior Notes due 2034, to the amendments of the indenture governing such notes entered into in 2021, including consent that the divestiture transactions referred to in the Lawsuit did not give rise to any default under the Indenture, and for the avoidance of doubt, a waiver of any alleged default under the Indenture in connection therewith. The terms of the settlement agreement are confidential. The settlement is not material to the Company's financial results or consolidated cash position.

07:29 EDT Invivyd announces addition to Russell 2000, Russell 3000 Indexes - Invivyd will be included in the Russell 2000 Index and the broad-market Russell 3000 Index, effective at the open of U.S. equity markets today.

07:28 EDT Skye Bioscience added to Russell 2000, Russell 3000 Indexes - Skye Bioscience has been included in the Russell 2000 Index and the broad-market Russell 3000 Index, effective at the U.S. market open on July 1, 2024, as part of the annual reconstitution of the Russell stock indexes.

07:25 EDT Bitfarms earns 189 bitcoin in June - Bitfarms provides its monthly production report and update on its fleet upgrade and expansion. "We continue to make progress on our fleet upgrades and new facility constructions, having installed over 39,000 new miners and deracked over 39,000 old miners so far this year. We exited the month with 11.4 EH/s installed, 10.4 EH/s operational and 25 w/TH efficiency," said Ben Gagnon, Chief Mining Officer. "Upgrades at all of our Quebec facilities are now complete and have significantly expanded our hashrate and improved our energy efficiency and gross mining margins across our portfolio. In Paraguay, our Paso Pe facility was energized with 4 of 5 warehouses and 6 of 8 hydro containers fully operational, contributing 2.5 EH/s with the remaining 0.6 EH/s to be energized in July. Severe weather in June, impacting both logistics and operations, contributed to moderate delays and temporary underperformance of miners." Executing on our strategy to cost-effectively expand our U.S. operating footprint, Bitfarms entered into a new agreement to develop a 120 MW site in Sharon, Pennsylvania. Situated strategically within the Pennsylvania-New Jersey-Maryland Interconnection, the largest wholesale electricity market in the U.S., and in a deregulated state, this site offers access to competitively priced electricity supply with opportunities to participate in demand response and curtailment programs, positioning Bitfarms to improve its corporate electricity price. The site is well suited for high intensity computing beyond Bitcoin mining, including HPC and AI services. June 2024 Select Operating Highlights 10.4 EH/s online at June 30, 2024, up 96% Y/Y and 39% M/M. 7.6 EH/s average online, up 19% M/M. 24.9 BTC/average EH/s, up 2% from the previous month with the installation of Bitmain T21 miners. 189 BTC earned, 21% higher M/M and 51% lower Y/Y. 6.3 BTC earned daily on average, equal to ~$384,000 per day based on a BTC price of $61,000 at June 30, 2024.

07:22 EDT Can-Fite announces improvement in patient with decompensated liver cirrhosis - Can-Fite BioPharma announced that a patient with liver decompensated cirrhosis who was treated with Namodenoson at the Soroka Medical Center in Israel under compassionate use showed an improvement in liver indices. This drug candidate is currently used in a pivotal Phase III study for patients with advanced liver cancer and a Phase IIb study for MASH. Decompensated cirrhosis is defined as an acute deterioration in liver function in a patient with cirrhosis and is characterized by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome, or variceal hemorrhage. While some drugs can treat symptoms, there is no therapeutic approach that has shown efficacy in slowing disease progression. In the past year Can-Fite has initiated a compassionate use program at the Soroka Medical Center, Beersheva, Israel, for the treatment of decompensated patients with Namodenoson. The first patient, a 63-year-old female with a history of decompensated primary biliary cirrhosis is now treated for one year with Namodenoson. Prior to the treatment with Namodenoson and despite best medical care for her underlying disease, she developed ascites and was admitted to the hospital with acute variceal bleeding. Currently, the patient shows improvement in liver function tests hematological parameters and FibroScan values and has not experienced any event of decompensation since starting treatment with Namodenoson. Namodenoson is known to induce liver protective effects in other liver pathologies, and Phase IIa data in patients suffering from MASH, responded positively to the drug, showing anti-inflammatory, anti-steatotic, and antifibrotic effects with a very favorable safety profile.

07:20 EDT Solaris, Warints, Yawi Communities correct 'record of false, misleading claims' - Solaris Resources and the Warints and Yawi Shuar communities correct the record of false and misleading claims made by anti-mining NGOs in relation to the social license for its Warintza Project in the province of Morona Santiago in southeastern Ecuador. Warintza Resides on the Ancestral Lands of the Warints and Yawi - The Ancestral Lands of these communities have been registered and clearly defined by the Government of Ecuador since 2002. These communities are registered legal entities under Ecuadorean law and the only parties that have any legal rights or authority over their Ancestral Lands. No other entity or association has any legal rights or authority over the Ancestral Lands of the Warints and Yawi. Warints and Yawi Recognized as Sole Holders of Their Ancestral Lands - The International Labor Organization documented the legitimacy of the Warints and Yawi as the sole holders of title to their Ancestral Lands and the legality of the Strategic Alliance governance structure created by Solaris as a mechanism of community consent for Warintza. The Strategic Alliance is managed by an Advisory Board of Directors made up of representatives of the Company and members of each community, democratically elected through their General Assemblies. Consultation Processes - The Ministry of Environment of Ecuador has carried out two consultation processes that have determined that the communities of Warints and Yawi are those directly influenced by Warintza. These successful consultation processes, supported by the communities, have allowed for the phase change of the Project from Initial Exploration to Advanced Exploration following the completion of an Environmental Impact Assessment and issuance of an Environmental License. Host Community Agreements - Solaris has explicit consent for the Project from the Warints and Yawi through its formal community agreements. These include an Impact and Benefits Agreement signed in 2020, later updated in 2022, and most recently in early 2024 to reflect the continued growth and advancement of the Project and its commitment to its host communities. All surrounding communities contribute employees to the Project and many of these have requested Solaris to engage in consultations regarding partnership in relation to their lands. Interprovincial Federation of Shuar Centers - In March 2024, Solaris signed a trilateral cooperation agreement with the Interprovincial Federation of Shuar Centers and the Alliance for Entrepreneurship and Innovation of Ecuador in the presence of a delegation of senior Ecuadorian government officials. FICSH is the highest authority and largest Shuar indigenous organization and was established by the Ministry of Social Welfare of Ecuador in 1964 and represents 143,000 Shuar indigenous people. Mr. David Tankamash, President of FICSH, commented at the time, "We support the Warints and Yawi communities and reject the efforts of foreign NGOs who act against the will and interest of our members."

07:16 EDT Bridger Aerospace appoints Dan Drohan to board of directors - Bridger Aerospace Group announced the appointment of aviation industry veteran Dan Drohan to the Company's Board of Directors. With the addition of Mr. Drohan, the Board will be comprised of nine members.

07:13 EDT Bridger Aerospace CEO Timothy Sheehy resigns, Sam Davis named interim - Bridger Aerospace Group announced changes to its management team and Board of Directors, including the resignation of the Company's CEO and Director, Timothy Sheehy, who is running for the U.S. Senate in the State of Montana. As a result, the Board of Directors has named Sam Davis, current Chief of Staff, as interim CEO and Jeffrey Kelter as Executive Chairman. The Nominating and Corporate Governance Committee of the Board, led by Board Member Rear Admiral Wyman Howard, will embark upon a search process for a permanent CEO.

07:12 EDT Bridger Aerospace acquires FMS Aerospace for $17.51M in equity - Bridger Aerospace Group has acquired FMS Aerospace. FMS, based in Huntsville, Alabama, is a turn-key provider of airframe modification and integration solutions for government and commercial customers including instrumentation, flight testing and airworthiness certification. The consideration for the transaction was $17.51 million in equity, with an additional contingent equity earn-out consideration of up to $3.09 million. The FMS transaction is an equity-only deal with a total value of $20.6 million with restricted common stock vesting in equal parts over a two-year period. It includes $17.51 million of restricted common stock issued at close with an additional $3.09 million to be paid pro-rata over two years, upon the satisfaction of an EBITDA target. For the full year ending December 31, 2023, FMS generated $10.3 million of revenue and net income of $2.5 million. FMS had approximately $2.0 million of cash and no debt at year end 2023. While the transaction is expected to be accretive to Bridger earnings on an annual basis after excluding transaction expenses and before anticipated synergies, the Company is not updating its guidance at this time.

07:11 EDT Centuri to be added to Russell 2000 index July 1 - Centuri Holdings announced that, as part of the annual reconstitution of the Russell stock indexes, Centuri has been added to the Russell 2000 index effective at the open of U.S. equity markets today, July 1... The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Membership in the Russell 2000(R) Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of December 2023, about $10.5 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, a prominent global index provider.

07:09 EDT Mobilicom receives follow-on order from defense manufacturer - Mobilicom has received a follow-on order from one of the largest U.S. drone manufacturers of "small-sized" drones. This defense manufacturer, with over $5 billion in annual sales, is equipping its drones with Mobilicom's SkyHopper PRO. These drones are sold to end-users in the U.S. defense market, including the U.S. Department of Defense. "This order, valued at approximately $500,000, is expected to be followed up with larger orders as this drone manufacturer continues to successfully compete and win government tenders for thousands of its drones." stated Mobilicom CEO and Founder Oren Elkayam.

07:08 EDT Applied Therapeutics added to Russell 3000 Index - Applied Therapeutics announced that the Company was added to the Russell 3000 Index, effective after the U.S. market closed on June 28, 2024, as part of the 2024 Russell indexes annual reconstitution.

07:08 EDT Eve Holding announces $94M in new equity financing - Eve Air Mobility has announced $94M in new equity financing from multiple investors. The funding, which includes the issuance of new shares of common stock and warrants, includes participation from a diverse group of global industrial companies that include Embraer, Nidec and additional financial investors. The new funding positions the company for future success and will support the continued development and manufacturing of the company's eVTOL. The company entered into agreements, dated as of June 28 for the issuance and sale of 23,500,000 new shares of the company's common stock at a purchase price of $4.00 per share, the exchange of certain warrants for shares of common stock, and the granting of warrants to certain investors. The private placement is expected to result in gross proceeds to Eve of $94M, before deducting other offering expenses. The equity funding is expected to close over the coming weeks, subject to the satisfaction of customary closing conditions.

07:06 EDT Actelis Networks announces exercise of warrants for $2.25M gross proceeds - Actelis Networks announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series A-2 warrants to purchase up to an aggregate of 999,670 shares of common stock of the Company originally issued in June 2024 having an exercise price of $2.00 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $2.25 million, prior to deducting placement agent fees and estimated offering expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash and the payment of additional $0.125 per new unregistered warrant, the Company will issue new unregistered warrants to purchase up to 1,999,340 shares of common stock. The new warrants will have an exercise price of $1.75 per share, will be immediately exercisable upon issuance and will have a term of twenty-four months from the issuance date. The offering is expected to close on or about July 2, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.

07:04 EDT Complete Solaria eliminates $67.6M of private equity debt - Complete Solaria had cancelled $67.6 million in debt from its balance sheet and been released from its obligations under that debt by its two private equity providers, Carlyle and Kline Hill Partners. On May 15, 2024, the Company announced that it had signed an agreement with Carlyle to set aside all of its financial claims in return for $10 million in cash. Today, we announce an equivalent deal with Kline Hill Partners for $8 million. On June 17, 2024, the Company announced that T.J. Rodgers had funded the $10 million payment to Carlyle by purchasing a convertible debenture security from the Company through Cantor Fitzgerald & Company. Today, we announce that the investment by T.J. Rodgers has been increased from $10 million to $18 million to fund both private equity settlement deals.

07:04 EDT 5E Advanced Metals initates customer qualification program - 5E Advanced Materials has initiated its customer qualification program, shipping samples of the Company's boric acid to multiple customers. This key advancement is expected to facilitate further commercial discussions and form the foundation for off-take and supply agreements. As the 5E operations team focuses on continued output from its flagship 5E Boron Americas complex, the commercial team remains consistently engaged with an expanding customer pipeline, and the qualification steps necessary for their respective end products. Customers currently in the qualification program include leading global materials science, consumer electronics, fiber optics, and specialty pharmaceutical glass companies which have a growing need to procure boric acid supply for their applications.

07:03 EDT BCE recommend shareholders reject TRC Capital below-market 'mini-tender offer' - BCE has received notice of an unsolicited mini-tender offer made by TRC Capital Investment Corporation to purchase up to 2,500,000 BCE common shares, or approximately 0.3% of the company's outstanding common shares, at a below-market price of C$43.40 per share. BCE does not endorse this unsolicited offer, has no association with TRC Capital or its offer, and recommends that shareholders do not tender their shares to this unsolicited mini-tender offer. BCE cautions shareholders that the mini-tender offer has been made at a price below market price for the BCE common shares. TRC Capital's unsolicited offer price of C$43.40 per share represents a discount of approximately 4.43% and 4.44%, respectively, to the closing price of the BCE common shares on the Toronto Stock Exchange and the New York Stock Exchange on June 24, 2024, the last trading day before the mini-tender offer was commenced.

07:02 EDT Avanos appoints Franchini to board of directors - Avanos Medical (AVNS) announced that Indrani Franchini has been appointed as a new independent member of the Avanos board of directors. Most recently, Franchini served as Executive Vice President and Chief Legal Officer at Alnylam Pharmaceuticals (ALNY)

06:54 EDT Macau reports June casino revenue up 16.4% to 17.69B patacas - Macau's gaming bureau reported June gross revenue from games of fortune in the region was up 16.4% year-over-year to 17.694B patacas. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Resorts (MLCO). Reference Link

06:48 EDT Ameresco announces debt financing from Nuveen - Ameresco announced that it has secured a $100M second lien debt financing with Nuveen Energy Infrastructure Credit. This strategic financial move underscores Ameresco's commitment to grow its business and provides balance sheet stability on attractive terms. The financing is leverage-neutral for the quarter ended June 30, 2024, as the net proceeds were used to pay off the remaining balance of the Company's Delayed Draw Term Loan A, with the remaining funds being applied to reduce the outstanding balance on the company's senior secured revolving credit facility.

06:45 EDT EU charges Meta over 'pay or consent' advertising model - The European Commission has informed Meta of its preliminary findings that its "pay or consent" advertising model fails to comply with the Digital Markets Act. In the Commission's preliminary view, this binary choice forces users to consent to the combination of their personal data and fails to provide them a less personalized but equivalent version of Meta's social networks. The Commission takes the preliminary view that Meta's "pay or consent" advertising model is not compliant with the DMA as it does not meet the necessary requirements set out under Article 5(2). In particular, Meta's model: Does not allow users to opt for a service that uses less of their personal data but is otherwise equivalent to the "personalized ads" based service. Does not allow users to exercise their right to freely consent to the combination of their personal data. By sending preliminary findings, the Commission informs Meta of its preliminary view that the company is in breach of the DMA. This is without prejudice to the outcome of the investigation. Meta now has the possibility to exercise its rights of defense by examining the documents in the Commission's investigation file and replying in writing to the Commission's preliminary findings. The Commission will conclude its investigation within 12 months from the opening of proceedings on March 25, 2024. In case of non-compliance, the Commission can impose fines up to 10% of the gatekeeper's total worldwide turnover. Such fines can go up to 20% in case of repeated infringement. Moreover, in case of systematic non-compliance, the Commission is also empowered to adopt additional remedies such as obliging a gatekeeper to sell a business or parts of it or banning the gatekeeper from acquisitions of additional services related to the systemic non-compliance. The Commission continues its constructive engagement with Meta to identify a satisfactory path towards effective compliance. Reference Link

06:38 EDT Olin announces epoxy resin anti-dumping proceeding against four countries - Olin (OLN), as a member of the Ad Hoc Coalition of Epoxy Resin Producers, comprised of Olin, Westlake Corporation (WLK), and Spolchemie, announced that the European Commission has initiated an anti-dumping proceeding concerning imports of epoxy resins from China, the Republic of Korea, Taiwan, and Thailand. This notice of initiation published in the European Union, or EU, Official Journal results from a complaint lodged by the Coalition to investigate the level of dumping practiced by Chinese, Korean, Taiwanese, and Thai exporters on the EU market and whether dumped imports from the four targeted countries have caused material injury to the European epoxy resin industry. The complaint alleges that exporting producers in the four targeted countries have injured the European epoxy resin producers by selling their products on the EU market at unfairly low prices that significantly undercut the prices of European producers. If the anti-dumping investigation concludes that injurious dumping practices from the four targeted countries have taken place, the European Commission is entitled to impose additional duties on imports of epoxy resins from the four targeted countries to restore a level playing field in the EU. If successful, this investigation will ensure that foreign epoxy resin producers cannot continue to benefit from sending dumped epoxy resins to the EU market and will restore the health of the EU epoxy resin industry, improve the resilience and security of domestic epoxy resin supply chains, enhance the jobs and communities that rely on the epoxy resin industry, and strengthen European economic security by preserving a critical EU manufacturing sector. The entire EU industrial complex would benefit from such an outcome.

06:35 EDT SpringWorks Therapeutics completes submission of NDA for mirdametinib - SpringWorks Therapeutics has completed the submission of a New Drug Application to the U.S. Food and Drug Administration for mirdametinib, an investigational MEK inhibitor, for the treatment of pediatric and adult patients with neurofibromatosis type 1- associated plexiform neurofibromas. The NDA submission includes data from the pivotal Phase 2b ReNeu trial, which evaluated mirdametinib in patients greater than or equal to 2 years of age with NF1-associated PN causing significant morbidity. Results were presented in an oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting and demonstrated that mirdametinib treatment resulted in significant objective response rates confirmed by blinded independent central review, deep and durable responses, improvement in pain and health-related quality of life as well as a manageable safety profile across both the adult and pediatric cohorts. The FDA and the European Commission have granted Orphan Drug designation for mirdametinib for the treatment of NF1. The FDA has also granted Fast Track designation for the treatment of patients greater than or equal to 2 years of age with NF1-PN that are progressing or causing significant morbidity and Rare Pediatric Disease designation for the treatment of NF1. In the second half of 2024, SpringWorks also plans to file a Marketing Authorization Application with the European Medicines Agency (EMA) for mirdametinib for the treatment of children and adults with NF1-PN.

06:33 EDT Babcock & Wilcox sells Denmark-based BWRS subsidiary to Hitachi Zosen for $87M - Babcock & Wilcox Enterprises has sold its Denmark-based Babcock & Wilcox Renewable Service subsidiary to Zurich, Switzerland-based Hitachi Zosen Inova for $87 million, subject to customary fees and adjustments. BWRS, which employs more than 160 people and provides aftermarket parts and services for waste-to-energy plants in northern Europe and the UK, was transferred to HZI upon closing on Friday, June 28, 2024.

06:16 EDT Shattuck Labs announces addition to Russell 2000, Russell 3000 Indexes - Shattuck Labs announced its addition to the Russell 2000 and Russell 3000 Indexes at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution. Shattuck's addition will be effective today when the U.S. equity markets open.

06:15 EDT Grifols says Biotest forecasts $1B U.S. sales of Yimmugo over next seven years - Grifols announced that Biotest forecasts approximately $1B in revenue from sales in the United States of its intravenous immunoglobulin Yimmugo during the next seven years, following recent Food and Drug Administration approval to treat primary immunodeficiencies. Yimmugo is the first Biotest medicine to be commercialized in the U.S. from its new FDA-certified "Next Level" production facility in Dreieich, Germany, which is already approved for production and marketing in Europe, where Yimmugo has been commercialized since late 2022. It will launch in the U.S. in the first quarter of 2025 and be distributed by Kedrion under a seven-year agreement with Biotest, part of an overarching Grifols Group channel strategy to ensure extensive reach and availability of its Ig therapeutics. Grifols Group and Kedrion have a longstanding collaborative relationship. Grifols itself will focus on continuing the growth of its leading and well-established intravenous and subcutaneous Ig treatments. Now, with Yimmugo, the Group's U.S. portfolio will have an additional option to address the growing demand for Ig to treat immunodeficiencies, in which part of the body's immune system is missing or does not function properly, and other medical conditions.

06:14 EDT AstraZeneca's Imfinzi, Lynparza recommended for approval in EU by CHMP - AstraZeneca's Imfinzi and Lynparza have been recommended for approval in the European Union, EU, as treatment for certain patients with primary advanced or recurrent endometrial cancer. Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi has been recommended for patients with mismatch repair proficient, pMMR, disease. The Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, based its positive opinion on a prespecified exploratory subgroup analysis by mismatch repair, MMR, status from the DUO-E Phase III trial, which was published in the Journal of Clinical Oncology in October 2023. This analysis showed a reduction in the risk of disease progression or death for pMMR patients in the Lynparza and Imfinzi arm by 43% versus the control arm.1 Results for dMMR patients showed a reduction in the risk of disease progression or death in the Imfinzi arm by 58% versus the control arm.

06:11 EDT Gravity's Ragnarok Online officially launches in China - GRAVITY Co. announced that Ragnarok Online was officially launched in China on June 28, 2024. After launching, it ranked second for All New Popular Games in WeGame. Ragnarok Online is a first-generation online MMORPG game that launched in South Korea in 2002, and is currently offered in 91 regions worldwide. The game in China is published by Shanghai Taren Network Technology Co., Ltd.

06:09 EDT IHS Holding announces results of 2024 annual meeting - IHS Holding announced the results of its 2024 Annual Meeting of Shareholders. At the Annual General Meeting, all the proposals put to the vote of shareholders were adopted, including the re-election of Frank Dangeard, Phuthuma Nhleko, Mallam Bashir El-Rufai and Nicholas Land as Independent Directors until the Company's 2025 AGM, and the proposal to amend and restate the Company's memorandum and articles of association, with the following key items now also included in the second amended and restated articles: declassify the Company's Board in two phases, with the periods extending through AGMs for fiscal years 2024 and 2025; reduce the threshold for shareholders to nominate directors from 30% previously to 10%, on an individual shareholder basis following the AGM for fiscal year 2024, and on an aggregate basis following the fiscal year AGM for 2025; reduce the threshold for shareholders to bring business before a general meeting from 30% previously to 10%, on an individual shareholder basis following the AGM for fiscal year 2024 and on an aggregate basis following the AGM for 2025; introduce a new right for shareholders owning at least 25% of shares to request a general meeting following the AGM for fiscal year 2025; and reduce the threshold to remove directors from requiring a special resolution previously to an ordinary resolution.

06:08 EDT Inseego announces debt reduction, restructuring transaction of convertible notes - Inseego Corp.has entered into a series of agreements, as part of its overall capital structure management to reduce its total debt and restructure its outstanding 3.25% convertible notes due 2025. As part of this initiative, the Company's three largest noteholders, whose holdings represent more than $125 million face value or nearly 80% of the outstanding 2025 Notes, have agreed to sell to the Company for cash, or exchange for long-term debt and equity of the Company, all of their 2025 Notes. This meaningful reduction and long-term extension of debt was executed at a 30% discount to the face value of the notes, further contributing to the improvement of the Company's capital structure. In implementing this strategic capital structure initiative, the Company executed three overall transactions on June 28, 2024, as follows: Convertible Debt Repurchase: the Company agreed to purchase all of the $45.9 million in face value of the 2025 Notes held by certain entities managed by Highbridge Capital Management, the second largest noteholder, for $32.1 million in cash, or $700 per $1,000 face value, plus accrued interest, the repurchase and debt reduction of which is expected to close on or about July 1, 2024; Repurchase Loan: to finance a portion of the Convertible Debt Repurchase, the Company entered into a loan facility and borrowed $19.5 million from South Ocean Funding, which is an affiliate of Golden Harbor and Tavistock Financial, LLC, and certain participant lenders; and Convertible Debt Exchange: the Company entered into binding term sheets to exchange $80.0 million of face value that represents all of the 2025 Notes held by North Sound Partners and Golden Harbor, the largest and third-largest noteholders, respectively, at the same 30% discount as the Highbridge Notes purchase, for a combination of new long-term debt and equity. The Company also announced that there was no change to its financial guidance provided for the second quarter of 2024.

06:05 EDT KBR green ammonia technology selected by Ocior Energy for plant in India - KBR announced its green ammonia technology, K-GreeN, has been selected by Ocior Energy for its plant located in Odisha's Gopalpur region, India. This will be the 10th KBR-licensed green ammonia plant globally and the first to be located in India. Under the terms of the contract, KBR will provide a technology license, proprietary engineering design, equipment, and catalyst solutions to Ocior for a green ammonia plant with capacity of 600 metric tons per day. Additionally, KBR will help Ocior's plant to achieve the optimal levelized cost of ammonia production.

06:02 EDT Meihua announces $3M share repurchase program - Meihua announced that its board of directors has approved and authorized a share repurchase program of up to $3M of the company's outstanding ordinary shares. The company intends to cancel all shares repurchased pursuant to this share repurchase program.

05:45 EDT Nio delivers 21,209 vehicles in June, 57,373 vehicles in Q2 - Nio announced its June and second quarter 2024 delivery results. Nio delivered 21,209 vehicles in June, representing an increase of 98.1% year-over-year. The deliveries consisted of 11,581 premium smart electric SUVs, and 9,628 premium smart electric sedans. Nio delivered 57,373 vehicles in the second quarter, representing an increase of 143.9% year-over-year. Cumulative deliveries of Nio vehicles reached 537,020 as of June 30.

05:37 EDT e.l.f. Beauty expands collaboration with Roblox - e.l.f. Beauty (ELF) is expanding its collaboration with Roblox (RBLX), making e.l.f. the first beauty brand to test real-world commerce on Roblox, powered by Walmart (WMT). The initiative will further e.l.f.'s mission to engage with its Roblox community of over 12M total visits and counting.

05:28 EDT Nyxoah submits final module of PMA application for Genio - Nyxoah announced that the company submitted the fourth and final module of its Premarket Approval, or PMA, application for Genio to the FDA. Genio is a different approach to hypoglossal nerve stimulation, or HGNS. Genio offers patients a fully-body MRI compatible, non-implanted battery solution, powered and controlled by a wearable. In March, Nyxoah announced the DREAM U.S. pivotal study data achieved a statistically significant reduction in the co-primary endpoints of 12-month AHI responder rate, per the Sher criteria, and ODI responder rate, both on an intent-to-treat basis, and that Genio is the only HGNS solution to show similar outcomes in supine and non-supine sleep.

05:19 EDT Zeekr delivers 20,106 vehicles in June - Zeekr announced its delivery results for June. Zeekr delivered 20,106 vehicles in June, representing a remarkable 89% year-over-year increase. Year-to-date, Zeekr has delivered 87,870 vehicles in 2024, a 106% growth over the same period last year. As of the end of June, Zeekr's cumulative deliveries reached 284,503. Notably, the company's Zeekr 001 surpassed 200,000 deliveries in June, setting a new benchmark in China's premium BEV market. In June, Zeekr entered into cooperation agreements with PT Premium Auto Prima in Indonesia and Sentinel Automotive Sdn. Bhd. in Malaysia, respectively, officially announcing its expansion into the Indonesian and Malaysian markets. Zeekr is currently present in over 25 major markets worldwide and aims to expand to more than 50 international markets this year, covering Europe, Asia, Oceania and Latin America.

05:15 EDT KKR to acquire controlling stake in Baby Memorial Hospital, terms undisclosed - KKR and Baby Memorial Hospital announced the signing of definitive agreements under which funds managed by KKR will acquire a controlling stake in BMH. KKR's investment will support BMH's efforts to address the growing need for quality, accessible healthcare services in India by advancing its efforts to build a leading pan-India network of hospitals, including through both organic and inorganic growth strategies. Founded in 1987 by K G Alexander, BMH is a multi-specialty hospital chains in Kerala, with a capacity of 1,000 beds across hospitals in Calicut and Kannur, and planned expansions across the region. BMH provides services with specialized treatment across 40 medical and surgical departments including cardiology, oncology, neurology, gastroenterology, pediatric and orthopedic care. BMH has invested in top-quality grade medical infrastructure and has multiple quality accreditations across hospitals in its network. KKR makes its investment from its Asian Fund IV. The transaction further builds on KKR's track record in the healthcare sector in India and across Asia Pacific, which includes: Max Healthcare, one of India's largest hospital networks; Healthium, a leading Indian medical devices company; Infinx, a tech-enabled healthcare revenue solutions provider; JB Pharma, a branded formulations pharmaceutical company in India; Gland Pharma, an Indian pure-play generic injectable pharmaceutical products company; PHC, a provider of medical equipment and clinical healthcare IT systems in Japan; Bushu Pharma, a pure-play contract development and manufacturing company in Japan; and Metro Pacific Hospitals, a private hospital chain in the Philippines. Additional details of the transaction are not disclosed.

05:04 EDT Boeing to acquire Spirit AeroSystems in $4.7B all-stock transaction - Boeing (BA) announced it has entered into a definitive agreement to acquire Spirit AeroSystems (SPR). The merger is an all-stock transaction at an equity value of approximately $4.7B, or $37.25 per share. The total transaction value is approximately $8.3B, including Spirit's last reported net debt. Each share of Spirit common stock will be exchanged for a number of shares of Boeing common stock equal to an exchange ratio between 0.18 and 0.25, calculated as $37.25 divided by the volume weighted average share price of Boeing shares over the 15-trading-day period ending on the second trading day prior to the closing. Spirit shareholders will receive 0.25 Boeing shares for each of their Spirit shares if the volume-weighted average price is at or below $149.00, and 0.18 Boeing shares for each of their Spirit shares if the volume-weighted average price is at or above $206.94. Boeing's acquisition of Spirit will include substantially all Boeing-related commercial operations, as well as additional commercial, defense and aftermarket operations. As part of the transaction, Boeing will work with Spirit to ensure the continuity of operations supporting Spirit's customers and programs it acquires, including working with the U.S. Department of Defense and Spirit defense customers regarding defense and security missions. Airbus (EADSY) and Spirit have also entered into a binding term sheet under which Airbus will acquire, assuming the parties entered into definitive agreements and receipt of any required regulatory approvals, certain commercial work packages that Spirit performs for Airbus concurrently with the closing of the Boeing-Spirit merger. In addition, Spirit is proposing to sell certain of its operations, including those in Belfast, Northern Ireland, Prestwick, Scotland, and Subang, Malaysia. The transaction is expected to close mid-2025 and is subject to the sale of the Spirit operations related to certain Airbus commercial work packages and the satisfaction of customary closing conditions, including regulatory and Spirit shareholder approvals.